Inhalers for respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma are medical devices which deliver medicine to prevent, control and treat symptoms and help reduce exacerbations. The medicine inside the inhaler goes directly into the airways when the patient breathe in.
The most notable market participants AstraZeneca Plc, Beximco Pharmaceuticals Ltd, Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc, Koninklijke Philips NV, OMRON Corp, PARI Respiratory Equipment, Inc., Teva Pharmaceutical Industries Ltd, and OPKO Health, Inc occupying a considerable share of the market owing to their offerings to the market.
AstraZeneca and Boehringer Ingelheim – Notable Market Participants in Respiratory Inhalers Market
Market leaders are involved in extensive research for the development of new respiratory inhalers with better efficiency and treatment outcomes. For instance, in February 2022, AstraZeneca partnership with Honeywell to develop next-generation respiratory inhalers. AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.
Many well-known as well as small local companies are present in the market to provide diversified products to its customers. The larger firms are adopting the strategy of acquiring small firms to enhance its product portfolio and expand its footprint in different geographies. Additionally, various companies are also undergoing other strategic alliances such as collaborations and others to garner their significance and remain competitive in the market. Few on the important key developments from the industry are mentioned below:
| Month & Year | News |
| Jan-2023 | AstraZeneca announced that FDA approved Airsupra (pressurized metered-dose inhaler (pMDI) in the US for the as-needed treatment or prevention of bronchoconstriction. Airsupra is a first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US. |
| Sep-2022 | Beximco Pharmaceuticals launched ONRIVA TRIO BEXICAP which is a dry inhaler, capsule. ONRIVA® TRIO BEXICAP® is the preparation of Indacaterol (150 µg), Glycopyrronium (50 µg), and Mometasone (160 µg). It works in 3 ways to control asthma symptoms. Indacaterol and Glycopyrronium help the muscles of lung airways to stay relaxed to prevent bronchoconstriction while Mometasone helps to decrease inflammation. ONRIVA® TRIO BEXICAP® is indicated as maintenance therapy in severe persistent asthma. |
| Jun-2021 | Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration. Cipla’s Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana. |
| Sep-2020 | FDA approved GSK’s Trelegy Ellipta for the treatment of both asthma and COPD in the US. The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US. |
